1号染色体短臂2区1带缺失是多发性骨髓瘤患者的一种新型预后标志物。
Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma.
作者信息
Chang Hong, Ning Yi, Qi Xiaoying, Yeung Joanna, Xu Wei
机构信息
Department of Laboratory Hematology, University Health Network, University of Toronto, Toronto, ON, Canada.
出版信息
Br J Haematol. 2007 Oct;139(1):51-4. doi: 10.1111/j.1365-2141.2007.06750.x.
The combination of fluorescence in situ hybridization with cytoplasmic light chain detection identified chromosome 1p21 deletion in 18 (20%) of 87 patients with multiple myeloma. 1p21 deletion was associated with higher serum calcium level, 13q deletion, and t(4;14). Patients with 1p21 deletions had a significantly shorter progression-free survival (PFS) (median 10.5 vs. 22.3 months, P = 0.0002) and shorter overall survival (OS) (median 33.9 months vs. not reached, P = 0.002) than those without 1p21 deletions. On multivariate analysis, which included deletions of 13q, TP53, t(4;14) and CKS1B amplification, 1p21 deletion remained as an independent risk factor for PFS (P = 0.01) and OS (P = 0.04).
荧光原位杂交与细胞质轻链检测相结合，在87例多发性骨髓瘤患者中的18例（20%）中检测到1号染色体1p21缺失。1p21缺失与较高的血清钙水平、13号染色体长臂缺失和t(4;14)相关。与无1p21缺失的患者相比，有1p21缺失的患者无进展生存期（PFS）显著缩短（中位值分别为10.5个月和22.3个月，P = 0.0002），总生存期（OS）也较短（中位值分别为33.9个月和未达到，P = 0.002）。在多变量分析中，纳入了13号染色体长臂缺失、TP53、t(4;14)和CKS1B扩增，1p21缺失仍然是PFS（P = 0.01）和OS（P = 0.04）的独立危险因素。
Zotero 插件